Allena Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Allena Pharmaceuticals's estimated annual revenue is currently $6M per year.
- Allena Pharmaceuticals received $53.0M in venture funding in December 2015.
- Allena Pharmaceuticals's estimated revenue per employee is $335,833
- Allena Pharmaceuticals's total funding is $2.9B.
- Allena Pharmaceuticals's current valuation is $37.1M. (January 2022)
Employee Data
- Allena Pharmaceuticals has 18 Employees.
- Allena Pharmaceuticals grew their employee count by -18% last year.
Allena Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Allena Pharmaceuticals?
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena's proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.
keywords:Biotechnology,Cleantech,Healthcare,Mobile,Pharmaceuticals,Wind Power
$2.9B
Total Funding
18
Number of Employees
$6M
Revenue (est)
-18%
Employee Growth %
$37.1M
Valuation
N/A
Accelerator
Allena Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP, Technical Operations | Reveal Email/Phone |
2 | CMC Project Manager | Reveal Email/Phone |
3 | Senior Accountant | Reveal Email/Phone |
4 | Chief Financial Officer | Reveal Email/Phone |
5 | VP, Finance | Reveal Email/Phone |
6 | Director, Quality Assurance | Reveal Email/Phone |
Allena Pharmaceuticals News
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme...
Get Allena Pharmaceuticals alerts: This table compares Allena Pharmaceuticals and Renovacor's revenue, earnings per share (EPS) and valuation.
Allena Pharmaceuticals (NASDAQ:ALNA) vs. Inhibikase Therapeutics (NYSE:IKT) Head to Head Review. Posted by admin on Apr 15th, 2022.
Company Presentation March 2021 Allena Pharmaceuticals, Inc. These slides, and the accompanying presentation, contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "inten ...
Brokerages expect Allena Pharmaceuticals Inc (NASDAQ:ALNA) to report ($0.48) earnings per share (EPS) for the current quarter, according to ...
Other Companies in Newton
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.6M | 18 | -5% | N/A |
#2 | $1.3M | 18 | 13% | N/A |
#3 | $2.9M | 19 | -17% | N/A |
#4 | $1.4M | 19 | N/A | N/A |
#5 | $2M | 20 | -50% | N/A |
Allena Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2011-11-17 | $15.0M | A | Bessemer Venture Partners, Frazier Healthcare | Article |
| 2014-12-05 | $25.0M | B | HBM Partners | Article |
| 2015-12-10 | $53.0M | C | Multiple | Article |